Inverse correlation of aberrant expression of fragile histidine triad (FHIT) protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma

References

• Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002;51(Suppl 6):VI1–VI9.
   PubMedGoogle Scholar
• Gores GJ. A spotlight on cholangiocarcinoma. Gastroenterology 2003; 125: 1536–8
   PubMedGoogle Scholar
• Heron DE, Stein DE, Eschelman DJ, Topham AK, Waterman FM, Rosato EL, et al. Cholangiocarcinoma: The impact of tumor location and treatment strategy on outcome. Am J Clin Oncol 2003; 26: 422–8
   PubMedGoogle Scholar
• Berman DM, Karhadkar SS, Maitra A, Montes-De-Oca R, Gerstenblith MR, Briggs K, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumors. Nature 2003; 425: 846–51
   PubMed Web of Science ®Google Scholar
• Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618–24
   PubMed Web of Science ®Google Scholar
• Huebner K, Croce CM. Cancer and the FRA3B/FHIT fragile locus: It's a HIT. Br J Cancer 2003; 88: 1501–6
   PubMed Web of Science ®Google Scholar
• Ishii H, Ozawa K, Furukawa Y. Alteration of the fragile histidine triad gene early in carcinogenesis: An update. J Exp Ther Oncol 2003; 3: 291–6
   PubMedGoogle Scholar
• Zhao P, Song X, Nin YY, Lu YL, Li XH. Loss of fragile histidine triad protein in human hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1216–9
   PubMed Web of Science ®Google Scholar
• Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC. Alterations of the FHIT gene in human hepatocellular cell carcinoma. Cancer Res 2000; 60: 1049–53
   PubMedGoogle Scholar
• Hao X.P, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, et al. Loss of Fragile Histidine Triad Expression in colorectal carcinomas and premalignant lesions. Cancer Res 2000; 60: 18–21
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: From gene discovery to cancer treatment and prevention. Lancet Oncol 2002; 3: 748–54
   PubMed Web of Science ®Google Scholar
• Koch E, Fiedler W, Tannapfel A, Ballhausen WG. Alteration of the fragile histidine triad gene in intrahepatic cholangiocarcinoma. Eur J Gastroenterol Hepatol 2003; 15: 907–13
   PubMedGoogle Scholar
• Kitahashi T, Tsujiuchi T, Satoh K. Aberrant transcription of FHIT gene in intrahepatic cholangiocellular carcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters. Exp Toxicol Pathol 2004; 56: 153–7
   PubMedGoogle Scholar
• Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, et al. Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma. Oncology 2001; 60: 242–51
   PubMedGoogle Scholar
• Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: Correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 2006; 24: 1152–60
   PubMed Web of Science ®Google Scholar
• Pace HC, Garrison PN, Robinson AK, Barnes LD, Draganescu A, Rosler A, et al. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci USA 1998; 95: 5484–9
   PubMed Web of Science ®Google Scholar
• Semba S, Huebner K. Protein expression profiling identifies cyclophilin A as a molecular target in Fhit-mediated tumor suppression. Mol Cancer Res 2006; 4: 529–38
   PubMedGoogle Scholar
• Nakagawa Y, Akao Y. Fhit protein inhibits cell growth by attenuating the signaling mediated by nuclear factor-kappaB in colon cancer cell lines. Exp Cell Res 2006; 312: 2433–42
   PubMed Web of Science ®Google Scholar
• Hu B, Wang H, Wang X, Lu HR, Huang C, Powell SN, et al. Fhit and CHK1 have opposing effects on homologous recombination repair. Cancer Res 2005; 65: 8613–6
   PubMed Web of Science ®Google Scholar
• Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 2004; 64: 5745–52
   PubMed Web of Science ®Google Scholar
• Kang YK, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 2002; 33: 877–83
   PubMed Web of Science ®Google Scholar
• Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol 2001; 35: 74–9
   PubMedGoogle Scholar
• Zen Y, Harada K, Sasaki M, Chen TC, Chen MF, Yeh TS, et al. Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1. Lab Invest 2005; 85: 572–81
   PubMed Web of Science ®Google Scholar
• Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 2005; 27: 973–80
   PubMed Web of Science ®Google Scholar